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Synopsis 
We investigated the effects and survival benefits of combined pre-operative triple combination 
chemotherapy with docetaxel, cisplatin, and S-1 (DCS therapy) and gastrectomy with 
para-aortic lymph node dissection (PAND) for advanced gastric cancer with para-aortic lymph 
node (PAN) metastasis. Our findings suggested that this multimodal therapy is extremely 
effective for advanced gastric cancer with PAN metastasis compared with conventional 
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Abstract 
Background: The prognosis of gastric cancer with para-aortic lymph node (PAN) metastasis is 
poor. We applied triple combination chemotherapy with docetaxel, cisplatin, and S-1 (DCS 
therapy) as pre-operative chemotherapy and investigated the outcome of the combination of 
this therapy and gastrectomy with para-aortic lymph node dissection (PAND). 
Methods: We retrospectively identified 44 patients with pathologically positive PAN who 
underwent curative surgery at Kanazawa University Hospital between 1990 and 2008. 
Among the 44 patients, 16 received pre-operative DCS therapy and subsequent surgical 
resection after 2 courses of the therapy. 
Results: Pre-operative DCS therapy showed high clinical response ratio (68.8%) and disease 
control ratio (100%). The pathological response ratio of resected specimen was 87.5%. At 2 
years after surgery, the overall survival ratio was 93.8% and relapse-free survival was 75.0%. 
Pre-operative DCS therapy was only independent prognostic factor in multivariate analysis. 
Grade 3/4 toxicity was observed only in 25.0% patients who underwent DCS therapy. Surgical 
complication was observed in 31.3% patients, and this ratio was equal to that of patients who 
did not receive DCS therapy. 
Conclusion: Multimodal therapy comprising combined pre-operative DCS therapy and 
gastrectomy with PAND was extremely effective and feasible for advanced gastric cancer with 
PAN metastasis. 
Keywords: gastric cancer, para-aortic lymph node metastasis, pre-operative chemotherapy, 
para-aortic lymph node dissection  
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Introduction 
Although the incidence of gastric cancer has decreased in recent decades, it is still one of the 
leading causes of cancer death in East Asia and Eastern Europe [1]. Recent improvements in 
therapeutic methods have considerably improved the prognosis of gastric cancer. This result 
is mostly attributed to the improved outcome of treatment of localized gastric cancer in 
relative early stage. However, the prognosis of unresectable cancers including hematological 
metastasis, peritoneal metastasis, and distant lymph node metastasis, such as para-aortic 
lymph node (PAN) metastasis, remains poor. More than 20% of patients with advanced gastric 
cancer develop PAN metastasis. Total resection of metastatic foci is difficult in gastric cancer 
with hematological or peritoneal metastasis, which should be treated with chemotherapy. 
Compared with the previously mentioned metastasis, lymph node metastasis can be 
completely resected without residual tumor; therefore, surgical intervention can improve the 
prognosis of patients with lymph node metastasis. Complete retrieval of these metastasized 
nodes is indispensable to improve the prognosis of such patients [2-6]. However, the prognosis 
is quite poor even after regional lymphadenectomy plus para-aortic lymph node dissection 
(PAND) are performed. For such patients, additional systemic chemotherapy is the potential 
and commonly used treatment.  
Several chemotherapeutic regimens with various kinds of combinations including 
5-fluorouracil (5-FU), cisplatin, irinotecan, and taxans were intensively investigated. 
Fluorouracil-based regimens were widely used and were the most effective chemotherapy for 
advanced gastric cancer. The Japanese Clinical Oncology Group 9912 Trial showed that S-1, 
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which is a novel orally administrated 5-FU analog, was a good alternative to continuous 
infusion of 5-FU for unresectable gastric cancer [7]. A multicenter phase Ⅲ  trial for 
unresectable gastric cancer (SPIRITS trial) comparing S-1 alone with S-1 plus cisplatin 
yielded a significantly higher response rate and improved overall survival in patients with S-1 
plus cisplatin [8]. Hence, S-1 plus cisplatin is considered as the existing standard regimen for 
advanced gastric cancer in Japan. Furthermore, the efficacy of triple combination regimen of 
ECF (epirubicin, cisplatin, and 5-FU) and DCF (docetaxel, cisplatin plus 5-FU) is reported 
from western countries, since these treatments are golden standard in western countries [9, 
10]. Recently, a novel triple combination with docetaxel, cisplatin, and S-1 (DCS therapy) has 
been reported as a powerful regimen for highly advance stage gastric cancer [11-13].  
Nevertheless, newly developed carcinostatics have shown remarkable proceeds; the response 
in gastric cancer remains limited and they mainly provide palliation or prolonged survival. 
Chemotherapy or radical resection severally did not produce satisfactory results. These 
observations indicate that novel approaches such as multimodal therapies are needed to 
improve the treatment outcome. However, the effect of post-operative chemotherapy remains 
limited despite of the recent developments [14, 15]. 
Recently, the efficacies of pre-operative treatment were reported in patients with locally 
advanced gastric cancer [16-18]. The tolerability and efficacy of these treatments were 
superior to those of post-operative chemotherapy. The potential benefits of pre-operative 
chemotherapy include these effects, reduction in cancer volume or downstaging of the tumor 
to make curative resection possible, extinguish micrometastasis, and furthermore assess the 
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sensitivity to anti-cancer drugs. Pre-operative treatment is a promising stratagem for 
advanced gastric cancer. Some effective pre-operative chemotherapeutic and 
chemoradiotherapeutic regimens have been reported in the recent years [16-18]. In these 
studies, the present chemotherapeutic regimens have been used together with surgical 
resection, but the targets of these treatments were patients with resectable cancer. These 
regimens may not be effective for patients with highly advance stage gastric cancer, such as 
PAN metastasis. Therefore, a new regimen that is powerful and safe in pre-operative setting 
is needed. We previously conducted Phase I study on DCS therapy in a preoperative setting 
for advanced gastric cancer with PAN metastasis, and the treatment was well tolerated with a 
quite high pathological response ratio [11]. 
The aim of this study was to investigate the survival benefit of gastrectomy with PAND on the 
heels of pre-operative DCS therapy for advanced gastric cancer patients with PAN metastasis. 
The survival outcome and toxicity of this multimodal therapy were examined and compared 
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Results 
Patient characteristics 
Patient demographics and tumor characteristics are summarized in Table Ⅰ. Pre-treatment 
clinical findings and histological features of surgical specimen (such as location, size, and 
depth of primary lesion; number of lymph node metastasis and PAN metastasis) did not differ 
between the groups. The surgical procedures were as follows: total gastrectomy in 18 16; 
distal gastrectomy in 8; pancreatoduodenectomy in 3; and proximal gastrectomy in 1, 
respectively, in patients without pre-operative DCS therapy. In patients with pre-operative 
DCS therapy. the surgical procedures were as follows: total gastrectomy in 11 9; distal 
gastrectomy in 6; and proximal gastrectomy in 1 respectively, All patients with pre-operative 
DCS therapy in present study had pathological findings suggesting presence of PAN 
metastasis before chemotherapy as pre-operative imaging diagnosis: 5 patients had residual 
cancer cells in PAN; 11 had no residual cancer cells and definite change after cancer 
disappearance in PAN [23]. The number of metastatic lymph node without residual cancer 
cells were 2-36 nodes (median 10) in all lymph nodes and 2-14 nodes (median 4) in PAN.  
Adjuvant chemotherapy 
The regimen of adjuvant chemotherapy in patients without pre-operative DCS therapy was 
altered with elapse of period. Regimen including intravenous administration of 5-FU was 
done in 10 patients, oral 5-FU in 11, and the other regimen in 4, 3 patients did not receive on 
patient’s request. The regimen of adjuvant chemotherapy in patients with pre-operative DCS 
therapy was DCS therapy done in 2 patients, S-1 in 8, and 6 patients did not receive on 
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patient’s request. 
Adverse events from pre-operative DCS therapy 
Treatment-related toxicities are shown in Table II. Toxicity of grade 3 or above, such as 
neutropenia (25.0%), leucopenia (18.8%), febrile neutropenia (6.3%)  and diarrhea (6.3%) 
were observed. No patient died of treatment-related toxicities. Treatment administration was 
delayed in 3 of the 16 patients (18.8%), and the cause of delayed administration was 
neutropenia in all patients. Dose reduction was performed in 3 cases (18.8%) due to 
neutropenia. Two patients (12.5%) could not complete 2 courses of DCS therapy. Nevertheless, 
surgery was possible in all patients within 2 to 4 weeks after termination of the last 
chemotherapy course. 
Clinical and pathological response to DCS therapy 
Clinical response rates are summarized in Table III. Clinical responses according to site were 
as follows: primary lesion, 81.3%; and lymph node metastasis, 68.8%; and hepatic metastasis, 
100%. The overall response ratio was 68.8%. The disease control ratio was 100%, and no 
patient had disease progression during pre-operative chemotherapy period.  
Pathological findings of surgically resected specimen are listed in Table Ⅳ. Pathological 
response (≥ grade1b) was observed 87.5% in primary lesion and 87.5% in lymph node 
metastasis. The ratio of no visible cancer cells according to site were as follows: primary lesion, 
25.0%; and lymph node metastasis, 25.0%. 
Surgical complication  
Among patients who did not receive pre-operative DCS therapy, surgical complications 
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developed in 10 patients (35.7%) (Table V) as follows: 8 had anastomotic leakage, 1 had 
pancreatic fistulae, 1 had bleeding after surgery, and 1 had lymphatic fistulae. , and 1 had 
peritoneal abscess. Among patients who received pre-operative DCS therapy, surgical 
complications developed in 5 patients (31.3%) as follows: 3 had pancreatic fistulae and 2 had 
lymphatic fistulae, respectively. The frequency of surgical complication were not different 
between the 2 groups. Two patients in without DCS therapy group required surgical 
intervention for postoperative hemorrhage and anastomotic leakage, respectively. In DCS 
therapy group, all complications were cured by conservative treatment. The number of 
complications in according to the Clavien–Dindo classification was 1 for grade I, 7 for grade II 
and 2 for grade III in without DCS therapy group. In DCS therapy group, the grading was 1 
for grade I and 4 for grade II. 
Recurrence after surgery 
Relapse occurred in 24 (85.7%) of 28 patients who did not receive pre-operative DCS therapy 
and 5 (31.2%) of 16 patients who received pre-operative DCS therapy. In patients without 
DCS therapy, recurrence occurred in lymph node in 5 patients, distant organs in 7, 
peritoneum in 3, and in composite sites 9. In patients with pre-operative DCS therapy, the 
site of relapse was lymph nodes in 3 patients and liver in 2. Lymph node recurrence was 
observed outside the custum field of lymph node dissection, ex. porta hepatis, near the hilum 
of kidney or iliac lymph nodes.  
Survival after surgical resection 
The 2-year and 5-year overall survival ratios were 32.9% and 24.0%, respectively, in patients 
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who did not receive pre-operative DCS therapy, and the 2-year ratios was 93.8% in patients 
who received pre-operative DCS therapy. Median follow-up was 35.1 months in patients with 
pre-operative DCS therapy; it was longer than median overall survival in patients without 
DCS therapy (18.2 months). The overall survival ratio was statistically higher in patients 
with pre-operative DCS therapy compared with that in patients without pre-operative DCS 
therapy (P=0.0001) (Figure 1). The 2-year and 5-year relapse-free survival ratios were 28.7%, 
and 16.3%, respectively, in patients who did not undergo pre-operative DCS therapy, and the 
2-year ratios was 75.0%, in patients with pre-operative DCS therapy. The relapse-free 
survival ratio was also statistically higher in patients with pre-operative DCS therapy 
(P=0.0082)  (Figure 2). In survival analysis, the factors contribute to overall survival were 
pre-operative DCS therapy, treatment period, number of lymph node metastasis and number 
of PAN metastasis in univariate analysis. In multivariate analysis, pre-operative DCS 
therapy was only independent factor contribute to overall survival (Table Ⅵ). 
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Discussion 
We obtained a very high clinical response ratio (68.8%) and disease control ratio (100%) with 
the pre-operative DCS therapy, and the pathological response ratio of resected specimen was 
87.5%. The overall survival ratio was 93.8% and relapse-free survival was 75.0% at 2 years 
after surgery; these values were statistically higher as compared to those of patients who did 
not receive pre-operative DCS therapy. Pre-operative DCS therapy was only independent 
prognostic factor in multivariate analysis. The toxicity profile and surgical complications were 
acceptable and manageable. Multimodal therapy combined with pre-operative DCS therapy 
and gastrectomy with PAND was an extremely effective and feasible therapy for advanced 
gastric cancer with PAN metastasis. 
Gastrectomy with lymphadenectomy is the mainstay of curative treatment for gastric cancer. 
Nevertheless, the appropriate degree of lymph node dissection remains controversial. The 
significance of curative resection in patients with positive PAN metastasis is not yet clear. A 
randomized trial in Japan to compare D2 lymphadenectomy alone with D2 lymphadenectomy 
plus PAND for gastric cancer (JCOG9501) did not suggest any difference in terms of survival 
between the 2 groups [24]. JCOG9501 study concluded that prophylactic PAND does not 
contribute to the survival benefit of resectable gastric cancer; however, this study does not 
deny the efficacy of therapeutic PAND. Curative resection with extended lymphadenectomy 
might be beneficial for patients with pathologically positive PAN metastasis. Nevertheless, 
limited patients gain benefit through radical dissection with PAND. Several factors indicating 
good prognosis of patients with PAN metastasis have been reported, including number of 
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metastatic PAN (<3 or 4) [3] and total number of metastatic lymph nodes (<11) [4]. In another 
report, patients with less than 15 total positive nodes and macroscopic type other than type 4 
had better survival outcome with R0 resection, including PAN retrieval [5]. We already 
reported the efficacy of selective lymphadenectomy of subgroups of PAN according to the 
location of the primary tumor [6]. These patients might benefit through radical dissection 
accompanied with PAND. However, the key factors in subsets of patients with PAN 
metastasis that may provide prognostic benefits with PAND remain unknown. Moreover, it is 
impossible to determine the presence of remnant cancer cells in lymph nodes after 
pre-operative chemotherapy through imaging or intraoperative findings. Therefore, we 
performed systemic resection of PAN, since imaging before chemotherapy suggested the 
presence of metastatic foci. 
The survival rate of these patients is low, and additional therapy is necessary besides curative 
resection to improve treatment outcome. Multimodal therapy combined with surgery and 
peri-operative chemotherapy currently appears to be a suitable option for resectable advanced 
gastric cancer. Some recent randomized trial of chemotherapy for unresectable gastric cancer 
failed to achieve good overall survival, in spite of good response rate and progression-free 
survival. It is difficult to improve the survival outcome in single-handed chemotherapy; 
however, this can be achieved in combination therapy including surgery and chemotherapy. 
ACTS-GC trial confirmed the efficacy of adjuvant chemotherapy with S-1 after D2 dissection 
for locally advanced gastric cancer [15]. However, the compliance of chemotherapy was low in 
this trial; the dose was decreased to 46.5% through the 12-month treatment schedule. 
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Similarly, adjuvant chemotherapy could not started in 6 of 16 patients in the present study. 
Tolerability is the principal concern of post-operative chemotherapy. Recent reports showed 
that pre-operative treatment is effective in patients with locally advanced gastric cancer 
[16-18], and the tolerability and efficacy of this treatment were superior to those of 
post-operative chemotherapy. MAGIC trial showed that peri-operative ECF therapy had 
significant survival benefit for operable gastric cancer [16]. Yoshikawa et al. reported the 
efficacy of pre-operative chemotherapy with irinotecan and cisplatin for advanced gastric 
cancer with PAN metastasis and/or bulky metastasis in regional lymph nodes. They reported 
a 3-year survival ratio of 27% and the pathological response ratio was limited to 17.0% [17]. 
Pathological response to preoperative chemotherapy may be a surrogate for long survival [25].  
Recently, there have been novel reports on DCS therapy for unresectable gastric cancer with 
extremely high response rates. Sato Y et al. reported a phase Ⅱ study of DCS therapy in 
patients with unresectable gastric cancer who received oral S-1 (40 mg/m2 b.i.d.) on days 1 to 
14 and intravenous cisplatin (60 mg/m2) and docetaxel (60 mg/m2) on day 8 every 3 weeks; 
their clinical response ratio was 87.1% [12]. Nakayama N et al. reported a phase Ⅰ study of 
DCS therapy in patients with unresectable gastric cancer patients who received oral S-1 (40 
mg/m2 b.i.d.) on days 1 to 14 and intravenous cisplatin (60 to 80 mg/m2) and docetaxel (40 
mg/m2) on day 1 every 4 weeks; their clinical response ratio was 69.2% [13]. Therefore, we 
applied DCS therapy, which is a powerful novel chemotherapy regimen, as pre-operative 
chemotherapy for advanced gastric cancer with PAN metastasis. In this study, the 2-year 
overall survival ratio was 93.8% and the pathological response ratio was 87.5%. These 
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findings suggest a markedly satisfactory outcome, even though poor prognosis was expected 
in the patient population of this study. However, Sato and Nakayama reported that although 
the regimens were very effective, they were too toxic to be used in a preoperative setting. 
Grade 3/4 neutropenia was observed in 77.4% patients by Sato Y et al. and in 42.9% patients 
by Nakayama et al. Treatment schedules remain a central issue in the search of a balance 
between good response and low toxicity. In our regimen, the dose of docetaxel and cisplatin 
was divided and these drugs were administered biweekly with anticipation of both decreased 
toxicity and preserved response.  
High perioperative morbidity and mortality rates are the main concerns of surgeons in cases 
with extended resection after pre-operative chemotherapy. Previous reports (JCOG9501) 
suggested that when performed by an experienced surgeon, lymphadenectomy of regional 
lymph node plus PAND may be a relatively safe treatment [24]. In general, lymphadenectomy 
after pre-operative chemotherapy was more difficult compared to lymphadenectomy without 
pre-operative chemotherapy because chemotherapy results in fibrous and edematous changes 
in the tumour site. The tissue damage caused by pre-operative chemotherapy may be 
resulting to high incidence of pancreatic fistulae and lymphatic fistulae in DCS group. Lower 
incidence of anastomotic leakage in DCS group may be a benefit of development in surgical 
instruments. In this study, the morbidity rate was 31.3% and mortality rate was 0%. These 
rates were considered acceptable, given the efficacy of this multimodal therapy.  
In conclusion, pre-operative DCS therapy is highly active against advanced gastric cancer 
with PAN metastasis, and this treatment is well tolerated with less toxicity and high rate of 
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pathological response. The favorable results of our study have raised the hope that this 
multimodal therapy may improve survival outcomes for patients with advanced gastric 
cancer accompanied with PAN metastasis, and this approach could became a promising 
strategy for treating patients with advanced gastric cancer with PAN metastasis in the future. 
However, since a small number of patients received this multimodal therapy in this study, 
further evaluations with large patient populations are required.  
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Patients and Methods 
We retrospectively identified patients with pathologically proven PAN metastasis who had 
undergone curative resection at our institute between 1990 and 2008. In all, 1355 patients 
underwent gastrectomy for gastric cancer at the Kanazawa University Hospital. Curative 
gastrectomy with lymphadenectomy of regional lymph node and PAN was performed in 121 
patients. Of these 121 patients, 49 had pathologically proven PAN metastasis. 5 of 49 these 
patients had hepatic metastasis and they were excluded in this study. We included these 49 
44 patients in our study. Traditional strategy for resectable gastric cancer in pre-operative 
images; even if diagnosed as accompanied with PAN metastasis, was that preceding total 
resection of cancer focus and the subsequent adjuvant chemotherapy. From 2005, we 
performed DCS therapy as a preoperative chemotherapy in advanced gastric cancer patients 
with PAN metastasis. To 2008, we have treated 18 16 patients of advanced gastric cancer with 
PAN metastasis with combined pre-operative DCS therapy and curative gastrectomy and 
lymphadenectomy of regional lymph node and PAN. Basically adjuvant chemotherapy was 
planned; the regimen was determined by the pathological effectiveness of pre-operative DCS 
therapy. For evaluating the efficacy of preoperative DCS therapy, patient characteristics and 
treatment outcome were analyzed. In addition, the survival benefit of this therapy was 
evaluated and compared with that of 31 28 patients who did not receive preoperative DCS 
therapy. 
Preoperative DCS therapy and surgery 
Preoperative DCS therapy with docetaxel and cisplatin [30-35 mg/m2 an intravenous 
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infusion] on days 1 and 15 with hydration and S-1 [orally 40 mg/m2 twice daily (b.i.d.) ] on 
days 1 to 14 every 4 weeks was administered, as described in a previous report [11]. Surgical 
resection was planned after 2 courses of preoperative DCS therapy. In patients who were 
judged to be candidates for curative resection, surgery was performed 2 to 4 weeks after the 
completion of the last course. Complete resection of primary lesion and regional 
lymphadenectomy plus PAND was performed. These 18 16 patients were included in our 
study cohort as the DCS group. A part of patients in DCS group this were overlapped with 
other studies we have previously published [11, 19]. 
Clinical assessment of surgery and cancer status 
In the present study, curative resection was defined as surgery without macroscopically 
evident residual cancer. Individual patient records and clinical, surgical, and pathological 
findings were collected from the institute database and evaluated according to the criteria of 
the Japanese Research Society for Gastric Cancer [20]. Surgical complications were assessed 
according to the Clavien-Dindo classification [21]. 
Clinical response and histological evaluation of surgical specimen 
In all patients, computed tomography and gastrointestinal fiberscopy were preformed before 
surgery; furthermore, in patients who received preoperative DCS therapy, pre-chemotherapy 
and post-chemotherapy evaluation was performed. The objective response to chemotherapy 
for metastatic lesions was evaluated according to Response Evaluation Criteria in Solid 
Tumours (RECIST; version 1.0) criteria and for primary lesions according to the Japanese 
Research Society for Gastric Cancer [22]. 
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All resected specimens were examined by same pathologist, and the pathological response to 
chemotherapy was evaluated according to the criteria of the Japanese Research Society for 
Gastric Cancer [22]. According to the amount of necrosis or disappearance of the tumor in the 
estimated total amount of the lesion, the tumors were graded as 0 to 3.Here, grade 0 meant 
neither necrosis nor cellular or structural change was observed throughout the lesion; grade 
1a meant necrosis or disappearance of the tumor was persistent in less than one-third of the 
whole lesion or only cellular or structural changes were visible; grade 1b meant necrosis or 
disappearance of the tumor was persistent in no more than two-third of the whole lesion; 
grade 2 meant necrosis or disappearance of the tumor was persistent in more than two-third 
of the whole lesion but visible tumor cells were still observed; and grade 3 meant completely 
necrotic lesion and/or fibrosis was observed with or without granulomatous changes, and no 
visible tumor cells were observed. Lymph nodes were also assessed in the same approach; 
lymph nodes with findings of grade 3 were assessed as the originally metastasized lymph 
nodes in which tumor cells were exterminated by pre-operative chemotherapy. 
Statistical analysis 
The significant differences in proportions between subgroups were determined with 
Chi-square test. Patient survival was calculated by the Kaplan-Meier method, and log rank 
test was used to compare survival rate among subgroups. Cox proportional model hazards 
regression was used for multivariate analysis. Prognosis variables of univariate significance 
were selected for inclusion in the multivariate model.  Statistical significance was defined as 
a p-value of <0.05. 
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Legends of the figure 
Figure 1 
The overall survival ratio of patients with pre-operative DCS therapy or without 
pre-operative DCS therapy.  
The 2-year survival ratio was 32.9% in patients without pre-operative DCS therapy, 93.8% in 
patients who received pre-operative DCS therapy. The difference was statistically significant 
(P=0.0001). 
Figure 2 
The relapse-free survival ratio of patients with pre-operative DCS therapy or without 
pre-operative DCS therapy.  
The 2-year survival ratio was 28.7% in patients without pre-operative DCS therapy, 75.0% in 
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Legends of the table 
Table1 
Pre-treatment clinical findings and histological features of surgical specimen did not differ 
between the groups. In pre-operative DCS therapy group, metastatic lymph node without 
residual tumor cells were 2-36 nodes (median 10) in all and 2-14 nodes (median 4) in PAN. 
Table2 
Toxicity of grade 3 or above were neutropenia (25.0%), leucopenia (18.7%), febrile neutropenia 
(6.3%) and diarrhea (6.3%). 
Table3 
Clinical responses ratios were as follows: primary lesion, 81.3%; lymph node metastasis, 
68.8%; overall, 68.8%. The disease control ratio was 100%. 
Table4 
Pathological response (≥ grade1b) was 87.5% both in primary lesion and lymph node. The 
ratio of grade 3 were 25.0% both in primary lesion and lymph node.. 
Table5 
Surgical complications were developed in 10 patients (35.7%) among without pre-operative 
DCS therapy group, and 5 patients (31.3%) among pre-operative DCS therapy group. 
Table6 
The factors contribute to overall survival were pre-operative DCS therapy, treatment period, 
number of lymph node metastasis and PAN metastasis in univariate analysis. In multivariate 
analysis, pre-operative DCS therapy was only factor contribute to overall survival. 
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DCS therapy P value
No. of patients 28 16  
SEX male/female 17/11 13/3 0.142 
Age-yr range (median) 31-78 (58) 42-78 (61) 0.533 
Clinical findings (before starting therapy) 
Tumor location U/M/L 7/7/14 6/3/7 0.583 
Tumor size-cm range (median) 2.5-15 (7.2) 4.0-10 (5.5) 0.234 
Depth of tumor invasion T2/T3/T4 9/12/7 6/5/5 0.922 
Borrmann macroscopic type 1/2/3/4 0/8/16/4 0/2/14/0 0.112 
Hepatic metastasis positive/negative 3/28 2/13 0.709 
Histological findings 
Histological type differentiated/undifferentiated 14/14 11/5 0.116 
Histological findings of lymph nodes 
Number of metastatic lymph nodes range (median) 2-67 (13) 5-49 (12) 0.591 
without residual cancer cells range (median) - 2-36(10) - 
Number of metastatic PAN range (median) 1-24 (4) 3-19 (3) 0.217 
without residual cancer cells range (median) - 2-14(4) - 
 
Table Ⅱ. Adverse events from chemotherapy 
 




leucopenia 0 4 2 1 43.8% 18.8% 
neutropenia 0 2 3 1 37.5% 25.0% 
anemia 3 0 0 0 18.8% 0% 
Nonhematological Toxicities 
nausea/vomiting 4 4 0 0 50% 0% 
diarrhea 0 0 1 0 6.3% 6.3% 
gastric hemorrhage 0 0 0 0 5.5% 5.5% 
febrile neutropenia - - 1 0 6.3% 6.3% 
 
Table Ⅲ. Clinical response to DCS therapy 
 
Clinical response No. of patients PD SD PR CR 
Primary lesion 16 0 3 13 0 
Lymph node 16 0 5 11 0 
liver 2 0 0 2 0 
overall 16 0 5 11 0 
 
Table Ⅳ. Pathological response to DCS therapy 
 
Pathological response No. of patients Grade 0 Grade 1a Grade 1b Grade 2 Grade 3 
Primary lesion 16 0 2 2 8 4 
Lymph node 16 0 2 3 7 4 
liver 2 0 0 0 1 1 
 
Table Ⅴ. Surgical complication 
 
 without pre-operative DCS therapy (n=28) with pre-operative DCS therapy (n=16) 
 number incidence number incidence 
Morbidity 10 35.7% 5 31.3% 
pancreatic fistulae 1 3.6% 3 18.8% 
lymphatic fistulae 1 3.6% 2 12.5% 
anastomotic leakage 8 28.6% 0 0% 
bleeding after surgery 1 3.6% 0 0% 
peritoneal abscess 0 0% 0 0% 
Mortality 0 0% 0 0% 
 
Table Ⅵ. Survival analysis 
 
 overall survival 
 univariate analysis multivariate analysis 
 P Hazard ratio (95% CI) P 
pre-operative DCS therapy (- vs. +) 0.001 0.061 (0.006 - 0.581) 0.015 
treatment period (-1999 vs. 2000-) 0.002 0.858 (0.247 – 2.988) 0.810 
adjuvant chemotherapy (- vs. +) 0.177 - - 
Borrmann macroscopic type (2/3 vs. 4) 0.078 - - 
histological type (intestinal vs. diffuse) 0.149 - - 
No. of lymph node metastasis (≤11 vs. 12<) 0.048 3.143 (0.737 – 13.397) 0.122 
No. of PAN metastasis (≤3 vs. 4<) 0.003 1.472 (0.258 – 1.472) 0.663 
 
